Sherleen Mohamdi-Osman, MD
Internal Medicine · Wake Island, HINPI 1871706358
Payments from drug & device makers
No general payments reported
No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.
How this compares
$0 in reported general payments places this provider in the 15th percentile of 655 internal medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 26 | $1,477 |
| Calcium Acetate | 19 | $1,360 |
| Nifedipine ErNifedipine | 34 | $593 |
| Bumetanide | 42 | $567 |
| Losartan Potassium | 24 | $249 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Wake Island
- Michael SavonaWailuku$520K
- Scott StromattKamuela$385K
- Keith WooHonolulu$106K
- Ronald PerryHonolulu$102K
- Laurie TomHonolulu$95K
- Yusuke MiyataniHonolulu$80K
- Joshua TanHonolulu$76K
- Jose de LeonHonolulu$52K
- Peter DeeHonolulu$49K
- James LumengHonolulu$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.